Want to see TSE:CRDL full AI Analyst Report?
Cardiol Therapeutics (CRDL) Income Statement
Cardiol Therapeutics Income Statement
Last quarter (Q2 2026), Cardiol Therapeutics's total revenue was $0.00. In Q2, Cardiol Therapeutics's net income was $-6.08M. See Cardiol Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Mar 26 | Mar 25 | Mar 24 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 78.76K | |
| $ 0.00 | $ -373.11K | $ -248.35K | $ -219.91K | $ 78.76K | |
| $ 34.32M | $ 39.90M | $ 29.54M | $ 41.34M | $ 38.74M | |
| Depreciation and Amortization | $ 101.98K | $ 373.11K | $ 248.35K | $ 219.91K | $ 220.42K |
| $ -34.21M | $ -36.30M | $ -27.88M | $ -30.71M | $ -38.44M | |
| $ -34.32M | $ -40.28M | $ -29.79M | $ -50.34M | $ -45.47M | |
| $ 497.42K | $ 3.60M | $ 1.66M | $ 10.41M | $ 7.03M | |
| $ -33.82M | $ -36.68M | $ -28.13M | $ -30.93M | $ -31.64M | |
| $ -33.82M | $ -36.68M | $ -28.13M | $ -11.52M | $ -24.72M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.39 | $ -0.51 | $ -0.44 | $ -0.18 | $ -0.57 |
| Diluted EPS | $ -0.39 | $ -0.51 | $ -0.44 | $ -0.18 | $ -0.57 |
| Weighted Average Shares Outstanding | 86.99M | 71.57M | 64.46M | 62.51M | 43.22M |
| Weighted Average Shares Outstanding (Diluted) | 86.99M | 71.57M | 64.46M | 62.51M | 43.22M |
Currency in CAD
